Jay S. Duker, M.D.
President & CEO and Board Director

Jay S. Duker, MD, is the President & CEO and Board Director of EyePoint Pharmaceuticals, a biopharmaceutical company that develops sustained-release medications to treat serious ocular disorders. Dr. Duker has devoted more than 30 years to the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical research, business, and academic settings. Dr. Duker joined EyePoint in 2020. Prior to becoming President & CEO in July 2023, Dr. Duker served EyePoint as President and Chief Operating Officer, and as Chief Strategic Scientific Officer. He also served on EyePoint’s Board of Directors from 2016-2020 prior to his re-appointment to the Board of Directors in July 2023.

Between 2001 and 2021, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston, Massachusetts. He has published over 345 journal articles, concentrating on retinal imaging, retinal vascular diseases, and drug delivery to the posterior segment. Dr. Duker remains in clinical practice, seeing patients with medical retinal disorders and intraocular tumors.

Dr. Duker is the founder of three successful start-up companies; SurgiSite Boston, the fifth busiest independent ophthalmology-only out-patient surgery center in the United States, the Boston Image Reading Center (BIRC), and Hemera Biosciences, the developer of HMR59, an AAV-based gene therapy for dry age-related macular degeneration that is now in a ph2 clinical trial after being acquired by Janssen in 2020. Dr. Duker was on the Board of Sesen Bio and served as its Chair. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.

George O. Elston
Chief Financial Officer & Head of Corporate Development

As Chief Financial Officer & Head of Corporate Development, George. O Elston leads EyePoint Pharmaceuticals’ financial, capital markets, and corporate development initiatives. Mr. Elston has leveraged his more than 30 years of diverse financial and senior leadership in the biopharmaceutical sector to propel the Company’s strategic, operational, and business goals forward. Prior to joining EyePoint in 2019, Mr. Elston served as Chief Financial Officer & Head of Corporate Development at Enzyvant Therapeutics, where he helped build the precommercial rare disease firm, leading to its eventual acquisition. He previously served as President and Chief Executive Officer at 2X Oncology, Inc., where he advanced the company from a spin-out into a multiprogram, clinical-stage organization, and held senior executive roles at Juniper Pharmaceuticals, Inc.; KBI Biopharma; and Optherion, Inc. Mr. Elston began his career in public accounting at PriceWaterhouseCoopers. He holds a B.B.A. in Accounting from Pace University and is a Certified Public Accountant. Mr. Elston currently serves as a Board Member of the DWS – DBX ETF Trust.

Ron Honig Esq.
Chief Legal Officer & Company Secretary

As Chief Legal Officer & Company Secretary, Ron Honig leads in-house counsel for EyePoint Pharmaceuticals, using his more than 30 years of experience in corporate governance, securities law compliance, and mergers and acquisitions to support the Company’s business priorities. Prior to joining EyePoint in 2018, Mr. Honig served as Vice President, Global Legal Affairs at Novanta, a publicly traded company that develops and manufactures technology solutions for medical devices and advanced industrial equipment makers worldwide. He also previously managed legal functions in senior executive roles at Lake Region Medical and ACMI. In addition to his diverse in-house legal experience, Mr. Honig has served as a corporate attorney for several law firms, including Mintz Levin in Boston. Mr. Honig began his career as a consultant with the Monitor Group. He holds a B.S. in Finance from the Wharton School at the University of Pennsylvania, a B.A.S. in Systems Engineering from the School of Engineering at the University of Pennsylvania, and a J.D. from Boston University, where he served as Editor-in-Chief of the Boston University Law Review.

Scott Jones
Chief Commercial Oficer

As Chief Commercial Officer of EyePoint Pharmaceuticals, Scott Jones draws on his significant experience commercializing drugs and devices globally to drive forward the commercialization of innovative ophthalmic products. Prior to joining EyePoint in 2019, Mr. Jones served as Chief Commercial Officer and Vice President, Business Development, at Notal Vision, where he built the organization’s commercial and growth strategy. Mr. Jones’ tenure at Notal Vision also included his role as President, in which he was responsible for developing a business model in the US that would allow for a telemonitoring platform to be covered by Medicare. He previously served as President of QLT Ophthalmics, where he created the strategy and infrastructure for a US commercial operation, and also navigated healthcare policy through roles of varying responsibility at Novartis, including Executive Director, Health Policy, and Executive Director and Head of Market Access and Government Affairs at Novartis Ophthalmics. Mr. Jones began his career with Geigy Pharmaceuticals as a medical representative and subsequently as a hospital sales representative for Ciba-Geigy Pharmaceuticals. He holds a B.S. in Chemistry, an M.A. in Political Science, and a Certificate in Public Administration from the University of Florida.

Isabelle Lefebvre
Chief Regulatory Officer
Isabelle Lefebvre
As Chief Regulatory Officer, Isabelle Lefebvre is responsible for EyePoint Pharmaceuticals’ regulatory strategy and compliance, with a focus on bringing innovative products to patients in the US and around the world. She oversees the Quality Management organization. Ms. Lefebvre has over 30 years of global regulatory affairs and compliance experience across all phases of drug development, including ophthalmic and ocular conditions. Prior to joining EyePoint in 2022, she served as Vice President, Head of Regulatory Science, at Hengrui USA, where she oversaw US and EU regulatory strategies for clinical programs in various phases of development. Ms. Lefebvre spent 10 years at Bausch Health Companies, Inc., where she held roles of increasing responsibility and led the successful approvals of two ocular drug products, LOTEMAX gel and VYZULTA®. Earlier in her career, Ms. Lefebvre held senior roles in regulatory strategy and affairs at Lundbeck, Inc.; Alpharma Pharmaceuticals; Bristol-Myers Squibb. Ms. Lefebvre holds a B.S. in Biochemistry from the University of Montreal and an M.S. in Regulatory Affairs from Northeastern University.
Jennifer Leonard
Chief People Officer & Senior Vice President, Information Technology

As Chief People Officer & Senior Vice President, Information Technology, Jennifer Leonard uses her more than 30 years of strategic human resources management and information technology (IT) expertise to drive EyePoint Pharmaceuticals’ talent and IT growth activities. Prior to joining EyePoint in 2018, Ms. Leonard served as the Head of Human Resources, Consumer Healthcare, and Global Functions at Sanofi US. From 2012 to 2015, she served as the Senior Vice President of Human Resources and Information Technology at PDI, Inc., a NASDAQ-listed healthcare commercialization company now named Interpace Diagnostics Group, Inc. Ms. Leonard has previously counseled a variety of global companies, including Novartis, Pharmacia/Pfizer, Boston Scientific Corporation, and Biovail Pharmaceuticals, on activities spanning employee coaching, organizational development planning and implementation, and M&A support. She also established and developed her own company, ImpactHR, LLC, which provided coaching and consulting services to the life sciences sector. Ms. Leonard began her career in human resources at Silicon Graphics (SGI). She holds a B.A. in both Psychology and Business Administration from the University of California at Los Angeles and an M.A. in Organizational Development and Human Resources from the University of San Francisco. Ms. Leonard is also recognized by the International Coaching Federation as an Associate Certified Coach and is a Hogan Assessment Certified Consultant.

Michael J. Maciocio
Senior Vice President, Manufacturing & Operations
Michael J. Maciocio

As Senior Vice President, Manufacturing & Operations, Michael Maciocio leads EyePoint Pharmaceuticals’ manufacturing and supply chain strategy, with a focus on ensuring clinical and commercial supply of innovative products is brought to patients within the US and globally. In support of this objective, Mr. Maciocio is responsible for manufacturing, supply chain, process engineering, and all CapEx planning and execution activities. He brings over 30 years of strategic and operational leadership experience within R&D and commercial manufacturing organizations on both site and global levels. Prior to joining EyePoint, Mr. Maciocio served as Vice President of Operations at Tedor Pharma, where he drove rapid facility and organizational expansion in support of several successful product launches. Mr. Maciocio also spent 16 years at Pfizer in roles of increasing responsibility within commercial manufacturing, supply chain, and global API planning & strategic sourcing. Earlier in his career, Mr. Maciocio held roles of increasing responsibility within manufacturing and process engineering at Hoechst Celanese / Clariant Corporation. Mr. Maciocio holds a B.S. in Chemical Engineering and an MBA from the University of Rhode Island.

Dario Paggiarino, M.D.
Senior Vice President & Chief Medical Officer

As Senior Vice President & Chief Medical Officer of EyePoint Pharmaceuticals, Dario A. Paggiarino, M.D., leads Company Clinical Development programs and Medical Safety.  He leverages more than 35 years of pharmaceutical industry experience with small molecules, biologics and devices/drug-device combinations across a variety of Therapeutic Areas. Prior to joining EyePoint in 2016, Dr. Paggiarino served as Senior Vice President and Chief Development Officer at lipid-targeted therapeutics company Lpath, where he advanced Phase I-II clinical programs in ophthalmology, oncology, and chronic pain. He also previously held the role of Vice President and Therapeutic Unit Head for Retinal Diseases at Alcon Laboratories, a division of Novartis, where he was responsible for advancing its retina pharmaceutical clinical development pipeline through regulatory approvals worldwide. Prior to that, Dr. Paggiarino served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D, with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases, and medical responsibilities for Macugen®, the first anti-VEGF treatment approved for age-related macular degeneration. Earlier in his career, he held research and development positions at Angelini Pharmaceuticals as well as Pharmacia Global R&D, where he was Clinical Program Director of Ophthalmology with responsibilities over Xalatan® one of the leading glaucoma therapies in the world, and Tecnis® IOLs. Dr. Paggiarino holds an M.D. in Medicine and General Surgery from the University of Rome La Sapienza and has authored numerous scientific articles.


Michael Pine
Chief Corporate Development & Strategy Officer
Michael Pine

As Chief Corporate Development & Strategy Officer, Michael Pine draws on his more than 20 years of industry experience in business development & licensing, commercial, and financial functions to generate growth and drive strategy at Eyepoint Pharmaceuticals. Prior to joining EyePoint in 2022, Mr. Pine served as Senior Vice President of Business Development and Strategy at Medexus Pharmaceuticals, where he managed the company’s inorganic growth strategy, facilitated partnerships and acquisitions, and supported several transactions critical to the growth of the organization. He also previously held a variety of roles spanning business development, commercial, operational, and strategy functions at Lupin Pharmaceuticals, Aralez Pharmaceuticals, and Novartis Pharmaceuticals. Earlier in his career, Mr. Pine held similar roles at Kos Pharmaceuticals, Organon Biosciences, and Pfizer, and served as an Investment Banking Analyst at JP Morgan Chase. Mr. Pine holds a B.S. in Consumer Economics from Cornell University and an M.B.A. from Columbia Business School.

Said Saim Ph.D.
Senior Vice President & Chief Technology Officer

As Senior Vice President & Chief Technology Officer, Said Saim, Ph.D., advances EyePoint Pharmaceuticals’ development and manufacturing activities through his strategic leadership, product development, and effective planning expertise, which spans more than 30 years. Prior to joining EyePoint in 2019, Dr. Saim served as Vice President, Pharmaceutical Development, at Collegium Pharmaceutical, where his responsibilities included managing formulation development, clinical trial manufacturing, and commercial manufacturing for controlled-release dosage forms. He also served as Senior Principal Scientist at Boehringer Ingelheim Pharmaceuticals, Inc., where he led a team of engineers and scientists in charge of process development, scale up, and technology transfer of North American products. Dr. Saim began his career as an Assistant Research Professor at the Higuchi BioSciences Center for Drug Delivery Research. He holds a Ph.D. in Chemical Engineering from the University of Kansas, has published 22 papers in engineering and science journals, and holds 18 patents.

Marcia Sellos-Moura, Ph.D.
Senior VP Program Leadership
Marcia Sellos-Moura, Ph.D.

Marcia Sellos-Moura, Ph.D., has broad biopharmaceutical experience in program and portfolio strategy and management, operations planning and execution, and in business development. For over 20 years, Dr. Sellos-Moura has worked across all phases of drug development and in multiple therapeutic areas. To date, she has been instrumental in the approval of four commercial products and the development of more than 25 therapeutic candidates. Prior to joining EyePoint, Dr. Sellos-Moura held various roles in program management, business strategy, and operations at Flagship Pioneering and Pioneering Medicines. She also served as Senior Vice President, Head of Program and Portfolio Management at Orphan Technologies, where she played a key role in the development of preclinical and clinical assets and the sale of the company. She previously held multiple positions of increasing responsibility in program management, operations, bioanalytical development, and biomarker discovery at Shire. Dr. Sellos-Moura began her career as a scientist at Transkaryotic Therapies working on the development of enzyme replacement therapies for rare diseases. She was awarded her Ph.D. in Biochemistry, Cell and Molecular Biology from Cornell University and a graduate degree in Biopharmaceutical International Regulatory Affairs from Northeastern University, has authored multiple manuscripts, and been granted several patents.